IDH1 antibody (AA 280-420)

Catalog No. ABIN3025025

This Mouse Monoclonal antibody specifically detects IDH1 in WB, FACS, IF and IHC (p). It exhibits reactivity toward Human.

Quick Overview for IDH1 antibody (AA 280-420) (ABIN3025025)

Target: IDH1 (Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IDH1 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: IDH1-1152

Product Details anti-IDH1 Antibody

Binding Specificity: AA 280-420

Characteristics: It recognizes a 45 kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming a-ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of a-ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Purification: Protein G affinity chromatography

Immunogen: A recombinant fragment (119 amino acid residues around aa 280-420) from the human protein was used as the immunogen for the IDH1 antibody.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal dilution of the IDH1 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Tris with 1  mM EDTA,  pH 9.0 or 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Western blot: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format : incubate for 30 min at RT (2)

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store the IDH1 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for IDH1

Target: IDH1 (Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1))

Alternative Name: IDH1

Background: It recognizes a 45  kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming a-ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of a-ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Pathways: Warburg Effect